A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Research output: Contribution to journalLetterpeer-review

5 Scopus citations

Abstract

Trial registration : ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153.

Original languageEnglish (US)
Article number54
Pages (from-to)54
JournalTranslational Neurodegeneration
Volume12
Issue number1
DOIs
StatePublished - Nov 16 2023

Keywords

  • Humans
  • Alzheimer Disease/drug therapy
  • Pilot Projects
  • Treatment Outcome
  • Immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cognitive Neuroscience
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this